查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586574

兒科癌症生物標記市場 - 全球產業規模、佔有率、趨勢、機會和預測，按適應症、類型、最終用途、地區和競爭細分，2019-2029F

Pediatric Cancer Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Type, By End-Use, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023年全球小兒癌症生物標記市場價值為8,1211萬美元，預計2029年將達到1,31,379萬美元，預測期內複合年成長率為8.52%。

市場概況
預測期 2025-2029
2023 年市場規模 81211萬美元
2029 年市場規模 131379萬美元
2024-2029 年複合年成長率 8.52%
成長最快的細分市場 白血病
最大的市場 北美洲

在精準醫學的進步和對兒童早期癌症檢測的認知不斷提高的推動下，全球兒科癌症生物標記市場正在成為醫療保健領域的重要組成部分。生物標記，包括遺傳、蛋白質組和表觀遺傳指標，是診斷、監測和預測兒科癌症治療反應的重要工具。兒童白血病、腦腫瘤和神經母細胞瘤等癌症盛行率不斷上升，增加了對更有效和個人化診斷解決方案的需求。對非侵入性診斷方法的日益重視進一步推動了該市場的發展，這種方法減少了年輕患者對侵襲性活體組織切片的需求。

製藥公司以及學術和研究機構正在大力投資生物標記的發現和開發，這在識別兒科腫瘤學特有的新型生物標記方面取得了重大突破。生物技術公司和醫院之間的合作，加上對孤兒藥開發的監管支持，加速了基於生物標記的診斷引入臨床實踐。生物標記與下一代定序（NGS）和液體活體組織切片技術等先進技術的整合提高了其精度和可靠性。

主要市場促進因素

兒童癌症盛行率不斷上升

生物標記研究和開發的進展

對個人化醫療的需求不斷成長

主要市場挑戰

兒科特異性生物標記的可用性有限

基於生物標記的診斷成本高昂

主要市場趨勢

日益關注早期診斷和篩檢

基因組學和蛋白​​質組學的技術進步

細分市場洞察

適應症見解

類型洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球兒科癌症生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症（白血病、神經母細胞瘤、中樞神經系統腫瘤、淋巴瘤、其他）
    • 依類型（甲胎蛋白 (AFP)、神經元特異性烯醇化酶 (NSE)、CD19、CD20、CD22、ALK（間變性淋巴瘤受體酪胺酸激酶基因）、其他）
    • 依最終用途（醫院、診斷實驗室、腫瘤中心、研究機構）
    • 按公司分類 (2023)
    • 按地區
  • 市場地圖

第 6 章：北美小兒癌症生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按類型
    • 按最終用途
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲小兒癌症生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按類型
    • 按最終用途
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區小兒癌症生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按類型
    • 按最終用途
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲小兒癌症生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按類型
    • 按最終用途
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲小兒癌症生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按類型
    • 按最終用途
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 市佔率及預測

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Myriad Genetics, Inc.
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies Inc.
  • BIOMERIEUX SA

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 25328

Global Pediatric Cancer Biomarkers Market was valued at USD 812.11 Million in 2023 and is expected to reach USD 1313.79 Million by 2029 with a CAGR of 8.52% during the forecast period.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 812.11 Million
Market Size 2029USD 1313.79 Million
CAGR 2024-20298.52%
Fastest Growing SegmentLeukemia
Largest MarketNorth America

The Global Pediatric Cancer Biomarkers Market is emerging as a vital segment in the healthcare landscape, driven by advancements in precision medicine and increasing awareness about early cancer detection in children. Biomarkers, which include genetic, proteomic, and epigenetic indicators, are essential tools in diagnosing, monitoring, and predicting treatment responses for pediatric cancers. The rising prevalence of cancers like leukemia, brain tumors, and neuroblastoma among children has amplified the demand for more effective and personalized diagnostic solutions. This market is further propelled by the growing emphasis on non-invasive diagnostic methods, which reduce the need for aggressive biopsies in young patients.

Pharmaceutical companies, along with academic and research institutions, are investing heavily in biomarker discovery and development, which has led to significant breakthroughs in identifying novel biomarkers specific to pediatric oncology. Collaborations between biotech firms and hospitals, coupled with regulatory support for orphan drug development, have accelerated the introduction of biomarker-based diagnostics into clinical practice. The integration of biomarkers with advanced technologies such as next-generation sequencing (NGS) and liquid biopsy techniques has enhanced their precision and reliability.

Key Market Drivers

Growing Prevalence of Pediatric Cancer

The increasing prevalence of pediatric cancer is a significant factor driving the growth of the Global Pediatric Cancer Biomarkers Market. Pediatric cancers, including leukemia, brain tumors, neuroblastoma, and lymphoma, although rare in comparison to adult cancers, remain one of the leading causes of disease-related mortality among children globally. In statistics released on February 2022, the World Health Organization (WHO) estimates that approximately 400,000 children are diagnosed with cancer every year. This figure highlights the urgency of addressing pediatric oncology, particularly as there are stark disparities in survival rates between high-income and low- to middle-income countries. In wealthier nations, advancements in medical care have improved survival rates, but in resource-limited regions, survival can be as low as 20%, underscoring the importance of global access to early diagnostic tools and treatments.

Growing awareness about pediatric cancer, along with improvements in early diagnosis, has resulted in a higher demand for biomarker-based diagnostic solutions. Biomarkers are essential in detecting cancers at their earliest stages, allowing for precise, timely interventions. This increased focus on personalized medicine, particularly for children, is further fueling the demand for reliable biomarkers capable of detecting, monitoring, and predicting the progression of pediatric cancers. Biomarkers enable healthcare providers to tailor treatment plans to the individual characteristics of each child's cancer, improving outcomes and reducing the side effects of more generalized treatment approaches.

In response to the rising cases of pediatric cancer, biotechnology and pharmaceutical companies are investing in research and development of novel biomarkers that specifically cater to the unique needs of pediatric oncology. These innovations are anticipated to not only improve the accuracy of diagnosis but also to enhance survival rates by providing more targeted therapies. Consequently, the global pediatric cancer biomarkers market is poised for significant growth as these tools become critical in the fight to improve early detection and treatment outcomes for children worldwide.

Advancements in Biomarker Research and Development

Advancements in biomarker research and development are playing a pivotal role in driving the Global Pediatric Cancer Biomarkers Market forward. The advent of precision medicine, which emphasizes personalized and targeted treatment approaches, has led to a heightened focus on understanding the molecular and genetic profiles of pediatric cancers. Researchers are utilizing cutting-edge technologies such as genomics, proteomics, and epigenetics to identify specific biomarkers for various pediatric cancer types. These biomarkers are crucial not only for early cancer detection but also for providing accurate prognoses and guiding individualized treatment plans based on the unique biology of each child.

The ongoing research efforts have led to the discovery of novel biomarkers, expanding the landscape of biomarker-based diagnostics and treatments in pediatric oncology. For instance, In February 2021, the International Agency for Research on Cancer (IARC) and St. Jude Children's Research Hospital announced a partnership to expand global pediatric cancer registries. This initiative is designed to enhance and broaden data collection in low- and middle-income countries, thereby supporting worldwide efforts to improve childhood cancer survival rates. These biomarkers help oncologists monitor disease progression, predict treatment responses, and offer insights into relapse risks, all of which are critical for improving survival rates. Advancements in technology are further accelerating progress in this field. For instance, next-generation sequencing (NGS) has significantly improved the ability to analyze the genetic alterations that drive pediatric cancers, enabling a more detailed and comprehensive understanding of the disease. In addition to NGS, liquid biopsy technology has emerged as a game-changer, offering a non-invasive, highly sensitive method to detect cancer cells through biomarkers in bodily fluids such as blood. Liquid biopsies not only allow for early diagnosis but also provide a means for continuous monitoring of cancer progression without the need for invasive procedures, improving patient comfort and care.

These technological innovations have enhanced the precision and accuracy of biomarker testing, which in turn has translated into better treatment outcomes for pediatric cancer patients. The rapid pace of development in this area is significantly benefiting the global market, as more sophisticated biomarker tools become available, enabling earlier interventions and reducing the overall burden of pediatric cancer. This continuous advancement is expected to further drive market growth, as these tools are crucial in shaping the future of pediatric cancer treatment.

Rising Demand for Personalized Medicine

The rising demand for personalized medicine is becoming a key driver in the growth of the Global Pediatric Cancer Biomarkers Market. Personalized medicine is an approach that tailors medical treatment to each patient's individual genetic, molecular, and environmental characteristics. In the context of pediatric oncology, where cancers tend to be highly heterogeneous, this approach is particularly valuable. Pediatric cancers often exhibit significant variation from patient to patient in terms of genetic mutations, molecular alterations, and disease progression. Biomarkers play a critical role in identifying these unique factors, allowing healthcare providers to design treatment plans that are specifically targeted to the individual biology of each child.

Biomarkers enable the detection of genetic mutations and molecular signals that drive cancer development, helping to pinpoint the specific pathways and mechanisms involved in a child's cancer. This precision in diagnosis leads to more effective treatment strategies that directly target the root causes of the cancer, as opposed to generalized treatment methods. By identifying and addressing these unique molecular characteristics, personalized medicine enhances the likelihood of successful treatment, while also minimizing the side effects often associated with traditional therapies. For example, targeted therapies may avoid the use of broad-spectrum chemotherapy, which can be unnecessarily toxic, thereby reducing harmful exposure for the patient.

The growing awareness of the benefits of personalized medicine in pediatric oncology has accelerated the adoption of biomarker-based diagnostic tools. These tools are increasingly seen as essential in guiding treatment decisions, ensuring that each child receives the most appropriate, effective therapies. In turn, this leads to better clinical outcomes, improved survival rates, and an enhanced quality of life for pediatric cancer patients. As personalized medicine continues to gain traction within the healthcare industry, the demand for pediatric cancer biomarkers is expected to rise significantly. This trend is likely to drive market growth, as biomarker technologies become indispensable in the quest for more individualized, precise cancer treatment options.

Key Market Challenges

Limited Availability of Pediatric-Specific Biomarkers

One of the major challenges facing the Global Pediatric Cancer Biomarkers Market is the limited availability of pediatric-specific biomarkers. While significant progress has been made in the development of cancer biomarkers for adults, pediatric oncology presents unique challenges due to the distinct nature of childhood cancers. Pediatric cancers often arise from different genetic mutations and molecular mechanisms compared to adult cancers, meaning that biomarkers identified for adult cancers may not be applicable to pediatric cases. The rarity of pediatric cancers further complicates the identification of specific biomarkers, as smaller patient populations make it difficult to conduct large-scale studies and clinical trials. Many childhood cancers are heterogeneous, meaning they vary significantly between patients, which increases the complexity of identifying reliable biomarkers for diagnosis and treatment. The lack of sufficient pediatric-specific biomarkers limits the ability of healthcare providers to utilize precision medicine approaches in treating pediatric cancer patients. The scarcity of well-validated biomarkers slows the development of new therapies and diagnostic tools tailored specifically to children, thereby restricting the growth of the pediatric cancer biomarkers market. Addressing this challenge requires greater investment in pediatric cancer research and more collaborative efforts between academic institutions, healthcare providers, and biotechnology companies to identify and validate novel biomarkers specific to pediatric oncology.

High Cost of Biomarker-Based Diagnostics

The high cost of biomarker-based diagnostics poses another significant challenge for the Global Pediatric Cancer Biomarkers Market. While biomarker-driven diagnostics have the potential to revolutionize pediatric oncology by enabling early detection and personalized treatment, these advanced tests are often expensive, making them inaccessible for many patients, particularly in low- and middle-income countries. The development, validation, and commercialization of biomarkers involve extensive research, clinical trials, and regulatory approvals, all of which contribute to the high costs associated with these diagnostic tools. The integration of cutting-edge technologies such as next-generation sequencing (NGS) and liquid biopsies into biomarker-based diagnostics further increases the overall expense. In addition to the high cost of the tests themselves, healthcare systems also face challenges related to the infrastructure and expertise required to implement biomarker-driven diagnostics effectively. For instance, advanced genomic sequencing technologies often require specialized equipment and trained personnel, which may not be readily available in many healthcare settings. As a result, the high cost of biomarker-based diagnostics limits their widespread adoption, particularly in resource-constrained regions. This cost barrier also impacts the ability of healthcare providers to offer personalized medicine approaches to pediatric cancer patients, ultimately hindering the market's growth. To overcome this challenge, there is a need for greater efforts to reduce the costs associated with biomarker-based diagnostics, as well as initiatives to improve access to these tools, especially in underserved regions.

Key Market Trends

Increasing Focus on Early Diagnosis and Screening

The increasing focus on early diagnosis and screening is becoming a critical factor in improving survival rates among pediatric cancer patients. Early detection is pivotal in cancer care, as it allows for interventions at a stage when the disease is most treatable, thereby significantly enhancing treatment success and long-term outcomes. Recognizing this, governments, healthcare organizations, and advocacy groups around the world are emphasizing the importance of early screening, leading to the development of advanced diagnostic tools aimed at detecting cancer at its earliest stages.

Biomarkers are playing an instrumental role in this movement toward early diagnosis. These biological indicators can signal the onset of cancer even before physical symptoms become evident, providing a much-needed window for timely interventions. Biomarkers offer precision in identifying the molecular changes and genetic mutations that drive pediatric cancers, enabling healthcare providers to diagnose the disease with greater accuracy and speed. The ability to detect cancer early not only improves the chances of effective treatment but also reduces the intensity of therapies required, lessening the physical and emotional burden on young patients and their families.

A key development in this area is the growing use of non-invasive biomarker-based tests, such as liquid biopsies. These tests allow for the monitoring of cancer progression and treatment response in real-time by analyzing biomarkers present in bodily fluids like blood, offering a less invasive alternative to traditional tissue biopsies. This is particularly beneficial for pediatric patients, as conventional biopsy procedures can be physically and emotionally taxing. Liquid biopsies also facilitate ongoing surveillance of cancer recurrence, helping clinicians adjust treatment plans promptly as the disease evolves. As healthcare systems place greater emphasis on early diagnosis and screening, the demand for pediatric cancer biomarkers is expected to increase substantially. This heightened demand is poised to drive the growth of the global pediatric cancer biomarkers market, as these tools become essential in the quest for early detection and improved survival rates among children diagnosed with cancer.

Technological Advancements in Genomics and Proteomics

Technological advancements in genomics and proteomics are playing a pivotal role in driving the Global Pediatric Cancer Biomarkers Market. The introduction of next-generation sequencing (NGS) technologies has transformed the field of cancer genomics by offering rapid, cost-effective, and comprehensive analysis of the entire genome. This has significantly improved the ability to identify genetic mutations, molecular alterations, and gene expression profiles that are specifically associated with pediatric cancers. NGS has opened new avenues for the discovery of novel biomarkers, which can help in early diagnosis, prognosis, and treatment decisions, leading to more personalized and targeted therapies for children with cancer.

Proteomics, the large-scale study of proteins and their functions, has also emerged as a critical field in cancer research. Proteins are the key effectors of cellular processes, and changes in protein expression, post-translational modifications, or interactions often underlie cancer progression. By studying these changes in pediatric cancers, researchers can identify protein-based biomarkers that provide deeper insights into the mechanisms driving cancer development. This has led to the identification of specific protein expression patterns linked to different types of pediatric cancers, enabling more precise biomarker-based diagnostics and therapeutic strategies.

The integration of genomics and proteomics has given rise to the development of multi-omic biomarkers, which combine data from both genomic and proteomic analyses to offer a more holistic view of cancer biology. These multi-omic approaches provide a more comprehensive understanding of how genetic mutations and protein alterations work together to drive cancer, leading to the discovery of more accurate and reliable biomarkers. These biomarkers are critical in improving the detection, monitoring, and treatment of pediatric cancers, allowing for more effective interventions and better patient outcomes. As technologies in genomics and proteomics continue to evolve, their contributions to pediatric oncology will become even more significant. With ongoing advancements, including improvements in data analysis, computational biology, and machine learning, the ability to discover more precise and personalized biomarkers will continue to expand, driving the growth of the global pediatric cancer biomarkers market and enhancing the future of pediatric cancer care.

Segmental Insights

Indication Insights

Based on the Indication, leukemia is the most dominant in the Global Pediatric leukemia, particularly acute lymphoblastic leukemia (ALL), is the most common cancer in children, accounting for a significant percentage of pediatric cancer cases. The high incidence of leukemia has led to substantial research efforts focused on identifying and validating biomarkers that can enhance diagnosis, prognosis, and treatment personalization. Biomarkers such as genetic mutations (e.g., BCR-ABL fusion gene), cytogenetic abnormalities, and minimal residual disease (MRD) detection are critical in managing leukemia. These biomarkers help in determining the specific subtype of leukemia, guiding treatment decisions, and predicting patient outcomes. For instance, the presence of certain genetic mutations can influence the choice of targeted therapies, which has revolutionized the treatment landscape for pediatric leukemia.

The growth in the pediatric leukemia biomarkers market is also driven by the increasing understanding of the molecular underpinnings of leukemia and the advancements in technologies such as next-generation sequencing (NGS). These technologies allow for the comprehensive profiling of genetic alterations, enabling clinicians to tailor treatment strategies effectively.

Type Insights

Based on the type segment, In the Global Pediatric Cancer Biomarkers Market, Alpha-fetoprotein (AFP) is the most dominant biomarker, particularly recognized for its critical role in pediatric oncology. AFP is primarily associated with liver cancer and certain germ cell tumors but has garnered significant attention for its application in diagnosing and monitoring hepatoblastoma, the most prevalent form of liver cancer in children. The ability of AFP to function as a reliable diagnostic and prognostic tool underscores its importance and makes it a focal point in pediatric cancer biomarker research.

The prominence of AFP in clinical practice stems from its utility across various aspects of patient management. Elevated levels of AFP in the blood serve as a key indicator of hepatoblastoma, facilitating timely diagnosis and the prompt initiation of appropriate treatment strategies. The dynamic monitoring of AFP levels throughout treatment allows healthcare providers to assess therapeutic responses effectively and detect potential recurrences early. This capability not only aids in refining treatment plans but also plays a significant role in improving overall patient outcomes.

Regional Insights

The North America region is currently dominating the Global Pediatric Cancer Biomarkers Market. This dominance can be attributed to several key factors, including advanced healthcare infrastructure, high research and development investments, and a well-established regulatory framework that facilitates the approval and utilization of novel biomarkers in clinical practice. The presence of leading biotechnology and pharmaceutical companies in North America contributes significantly to the market's growth, as these organizations actively engage in the development and validation of pediatric cancer biomarkers. Numerous research institutions and universities in the region are dedicated to studying pediatric cancers, leading to innovative discoveries and breakthroughs that enhance the understanding of various biomarkers, including Alpha-fetoprotein (AFP) and others.

North America has a higher prevalence of pediatric cancers compared to other regions, which drives demand for effective diagnostic and prognostic tools. The integration of advanced diagnostic technologies, such as next-generation sequencing and liquid biopsies, further boosts the market by improving the accuracy and efficiency of biomarker testing in pediatric patients. Strong collaborations between hospitals, research institutions, and diagnostic laboratories facilitate a robust ecosystem for biomarker research and development. This collaborative environment, coupled with a commitment to improving pediatric cancer outcomes, positions North America as the leading region in the Global Pediatric Cancer Biomarkers Market, paving the way for ongoing advancements and enhanced patient care.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Myriad Genetics, Inc.
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies Inc.
  • BIOMERIEUX SA

Report Scope:

In this report, the Global Pediatric Cancer Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Cancer Biomarkers Market, By Indication:

  • Leukemia
  • Neuroblastoma
  • CNS Tumors
  • Lymphoma
  • Others

Pediatric Cancer Biomarkers Market, By Type:

  • Alpha-fetoprotein (AFP)
  • Neuron-specific enolase (NSE)
  • CD19
  • CD20
  • CD22
  • ALK (anaplastic lymphoma receptor tyrosine kinase gene)
  • Others

Pediatric Cancer Biomarkers Market, By End-Use:

  • Hospital
  • Diagnostic Laboratories
  • Oncology Centers
  • Research Institutions

Pediatric Cancer Biomarkers Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Cancer Biomarkers Market.

Available Customizations:

Global Pediatric Cancer Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Pediatric Cancer Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Leukemia, Neuroblastoma, CNS Tumors, Lymphoma, Others)
    • 5.2.2. By Type (Alpha-fetoprotein (AFP), Neuron-specific enolase (NSE), CD19, CD20, CD22, ALK (anaplastic lymphoma receptor tyrosine kinase gene), Others)
    • 5.2.3. By End-Use (Hospital, Diagnostic Laboratories, Oncology Centers, Research Institutions)
    • 5.2.4. By Company (2023)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Pediatric Cancer Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Type
    • 6.2.3. By End-Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pediatric Cancer Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End-Use
    • 6.3.2. Mexico Pediatric Cancer Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End-Use
    • 6.3.3. Canada Pediatric Cancer Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End-Use

7. Europe Pediatric Cancer Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Type
    • 7.2.3. By End-Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Pediatric Cancer Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End-Use
    • 7.3.2. Germany Pediatric Cancer Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End-Use
    • 7.3.3. United Kingdom Pediatric Cancer Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End-Use
    • 7.3.4. Italy Pediatric Cancer Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End-Use
    • 7.3.5. Spain Pediatric Cancer Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End-Use

8. Asia-Pacific Pediatric Cancer Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Type
    • 8.2.3. By End-Use
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Pediatric Cancer Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End-Use
    • 8.3.2. India Pediatric Cancer Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End-Use
    • 8.3.3. South Korea Pediatric Cancer Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End-Use
    • 8.3.4. Japan Pediatric Cancer Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End-Use
    • 8.3.5. Australia Pediatric Cancer Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End-Use

9. South America Pediatric Cancer Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Type
    • 9.2.3. By End-Use
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pediatric Cancer Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End-Use
    • 9.3.2. Argentina Pediatric Cancer Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End-Use
    • 9.3.3. Colombia Pediatric Cancer Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End-Use

10. Middle East and Africa Pediatric Cancer Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Type
    • 10.2.3. By End-Use
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pediatric Cancer Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End-Use
    • 10.3.2. Saudi Arabia Pediatric Cancer Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End-Use
    • 10.3.3. UAE Pediatric Cancer Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
    • 10.3.4. Market Share & Forecast
        • 10.3.4.1.1. By Indication
        • 10.3.4.1.2. By Type
        • 10.3.4.1.3. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. F. Hoffmann-La Roche Ltd
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Abbott Laboratories Inc.
  • 14.3. Siemens Healthineers AG
  • 14.4. Thermo Fisher Scientific Inc.
  • 14.5. QIAGEN NV
  • 14.6. Myriad Genetics, Inc.
  • 14.7. Danaher Corporation
  • 14.8. Bio-Rad Laboratories, Inc.
  • 14.9. Agilent Technologies Inc.
  • 14.10. BIOMERIEUX SA

15. Strategic Recommendations

16. About Us & Disclaimer